This website uses cookies. By continuing to browse this website you are agreeing to our use of cookies. Find out more by reading our privacy policy. Read more
Photos
The images on this website are for news media use only. If you have comments or questions, please do not hesitate to contact us.
 | Anne Marie Kverneland, employee representative |
 | Cameron Hubbard, USA Cameron has type 1 diabetes |
 | Nina Oldenburg, Germany Nina Oldenburg has type 1 diabetes |
 | Bruno Angelici |
 | Sude Iğdır, Turkey Sude Iğdır has type 1 diabetes |
 | Göran Ando, Chairman |
 | Hannu Ryöppönen, member of the Audit Committee |
 | Rutha Gordon, USA Rutha has type 2 diabetes |
 | Nancy Johnson, USA Nancy has type 2 diabetes |
 | Henrik Gürtler |
 | Peter Rot, Germany Peter Roth has type 2 diabetes |
 | Jeppe Christiansen, Vice Chairman |
 | Jay Luckey, USA Jay has haemophilia B |
 | Guillermo Nicolás Pirazzini, Argentina Guillermo Nicolás Pirazzini has haemophilia A |
 | Liz Hewitt, member of the Audit Committee |
 | Kazuyoshi Aoki, Japan Kazuyoshi Aoki has haemophilia A |
 | Søren Thuesen Pedersen, employee representative |
 | Stig Strøbæk, employee representative |
 | Thomas Paul Koestler |
 | Ulrik Hjulmand-Lassen, employee representative |
 | Novo Nordisk Inflammation Research Center and Novo Nordisk Type 1 Diabetes R&D Center in Seattle, US |
 | Novo Scholarships In January 2013 Novo Scholarships totalling 2,6 million Danish kroner were awarded to 41 of the country’s most talented MSc students in the biotechnological and pharmaceutical sciences |
 | Research and development at Novo Nordisk R&D Centre China in Beijing, China |
 | New Novo Nordisk R&D Centre China in Beijing, China. |
 | New Novo Nordisk R&D Centre China in Beijing, China. |
 | Degludec molecule - Novo Nordisk |
 | Research and development at Novo Nordisk R&D Centre China in Beijing, China |
 | NovoPen® 4 NovoPen® 4 is a durable insulin pen which allows patients to change their insulin cartridge whilst retaining the same pen. 2010 is the 25th anniversary for NovoPen® which was the first insulin pen ever produced. |
 | FlexTouch® FlexTouch® is the latest prefilled device from Novo Nordisk offering a new insulin delivery experience for users as it is the only prefilled insulin pen with no push-button extension. |
 | FlexPen® Next Generation FlexPen® is a pre-filled insulin delivery device, eliminating the step of loading insulin into the delivery system. |
 | NovoPen Echo® Insulin pen specifically designed to meet the needs of children with diabetes. First ever insulin pen to offer a combination of a memory function with a half-unit dosing option. Will be launched in 2010. |
 | NovoPen Echo® Skins An additional feature of the NovoPen® Echo is the option of customising the look of the pen with a number of colourful skins. Will be launched in 2010. |
 | NovoTwistTM New needle designed for use with the insulin delivery device FlexPen® and Victoza® Pen. The needle, which has a simple ‘just twist’ attachment and detachment, makes injection easier for people with diabetes. |
 | Research and development of liraglutide at Novo Nordisk in Bagsværd, Denmark |
 | Liraglutide molecule - Novo Nordisk |
 | Mads Krogsgaard Thomsen Executive vice president and chief science officer (CSO) |
 | Pen device |
 | NovoFine® NovoFine® Autocover® was the world's first safety pen needle, designed to help prevent accidental needlestick injuries. |
 | InnoLet® Has been designed specifically for people with poor eyesight, reduced manual dexterity or learning difficulties to better enable them to manage insulin therapy. |
 | Haemophilia Treatment of haemophilia patient. |
 | Cartridecacog molecule |
 | mAb2021 molecule |
 | N8-GP molecule |
 | N9-GP molecule |
 | Turoctocog molecule |
 | NovoSeven® prefilled syringe |
 | R&D, haemophilia |
 | Lars Rebien Sørensen President and Chief Executive Officer (CEO) |
 | R&D, haemophilia |
 | R&D, haemophilia |
 | Team Novo Nordisk |
 | Team Novo Nordisk |
 | Team Novo Nordisk |
 | Cartridges |
 | Collecting crystals |
 | FlexTouch® Tresiba® filling |
 | Assembly line Tresiba® in FlexTouch® |
 | Vials |
 | Team Novo Nordisk |
 | Team Novo Nordisk |
 | Team Novo Nordisk |
 | Team Novo Nordisk |
 | Team Novo Nordisk |
 | Jesper Brandgaard Executive Vice President and Chief Financial Officer (CFO) |
 | Lars Fruergaard Jørgensen Executive vice president and chief information officer (CIO) |
 | Lise Kingo Executive Vice President and Chief Of Staffs (COS) |
 | Jakob Riis Executive Vice President and Chief Of Staffs (COS) |
 | Kåre Schultz Executive Vice President and Chief Operating Officer (COO) |
 | Mads Krogsgaard Thomsen Executive Vice President and Chief Science Officer (CSO) |
 | Research and development at Novo Nordisk Inflammation Research Center in Seattle, US |
 | Research and development at Novo Nordisk in Gentofte, Denmark |
| Research and development of liraglutide at Novo Nordisk in Bagsværd, Denmark |
 | Research and development at Novo Nordisk in Måløv, Denmark |
 | Research and development at Novo Nordisk in Bagsværd, Denmark |
 | Research laboratory at Novo Nordisk in Måløv, Denmark |
 | Research and development at Novo Nordisk in Bagsværd, Denmark |
| Liraglutide® molecule - Novo Nordisk |
 | NordiPen® With human growth hormone for treatment of growth disorders. |
 | New Novo Nordisk Corporate Centre The new Novo Nordisk Corporate Centre is expected to be ready for occupancy at the end of 2013. Illustration by Henning Larsen Architects. |
 | New Novo Nordisk Corporate Centre The new Novo Nordisk Corporate Centre is expected to be ready for occupancy at the end of 2013. Illustration by Henning Larsen Architects |
 | New Novo Nordisk Corporate Centre The new Novo Nordisk Corporate Centre is expected to be ready for occupancy at the end of 2013. Illustration by Henning Larsen Architects. |
 | Corporate headquarters Novo Nordisk has its corporate headquarters in Bagsværd, Denmark. |
 | Corporate headquarters |
 | Novo Nordisk flag |
 | Corporate headquarters Arial photo of Novo Nordisk headquarters in Bagsværd, Denmark. |
 | Novo Nordisk's dispensers for hormone tablets. |
 | Hillerød, Denmark Filling of modern insulin in vials in plant in Hillerød, Denmark. |
 | Tianjin, China Novo Nordisk's insulin plant |
 | Clayton, North Carolina, USA Insulin manufacturing plant |
 | Montes Claros, Brazil Visual inspection of insulin vials, Brazil |
 | Hillerød, Denmark Novo Nordisk's highly advanced plant in Hillerød, Denmark. |
 | Hillerød, Denmark The NovoSeven® factory in Hillerød. |
 | Hillerød, Denmark Arial photo of Novo Nordisk's plant in Hillerød, Denmark. |
 | Hillerød, Denmark The production of Novo Nordisk's insulin pens takes place in the highly advanced plant in Hillerød, Denmark. |
 | Måløv, Denmark Arial photo of Novo Nordisk's plant in Måløv, Denmark. |
 | Kalundborg, Denmark Packing of insulin pens in the plant in Kalundborg, Denmark. |
 | Kalundborg, Denmark Novo Nordisk's fermentation factory in Kalundborg, Denmark. |
 | Kalundborg, Denmark Arial photo of Novo Nordisk's fermentation factory in Kalundborg, Denmark. |
 | Kalundborg, Denmark Novo Nordisk's fermentation factory in Kalundborg, Denmark. |
 | August and Marie Krogh (1874-1949) August Krogh a professor at the University of Copenhagen, received the Nobel Prize in physiology in 1920. His wife, Marie Krogh, was a doctor and a researcher in metabolic diseases. |
 | Hans Christian Hagedorn (1888-1971) and August Krogh founded Nordisk Insulinlaboratorium in 1923. |
 | Harald Pedersen (1878-1966) Harald Pedersen, an unusually talented inventor, founded Novo Terapeutisk Laboratorium together with his brother Thorvald Pedersen. |
 | Thorvald Pedersen (1887-1961) a qualified pharmacist, founded Novo Terapeutisk Laboratorium together with his brother Harald Pedersen in 1925. |
 | Insulin Leo Was Denmark’s first insulin product. |
 | Insulin Novo |
 | The Novo syringe together with NovoPen® In 1925 Harald Pedersen designed a special syringe – the Novo syringe – with which the patients could inject themselves with insulin. In 1985 Novo Industri introduced the first NovoPen® (bottom). |
 | Insulin production at Novo in the 1930s |
 | Production of insulin Some of the first machines for production of insulin at Novo. |
 | Changing Diabetes® in Children In December 2008, Novo Nordisk announced a five-year programme to change the future of children with type 1 diabetes in the least developed countries (LDCs). In November 2009, Bangladesh was added to the programme as the sixth country. |
 | Lotte Bjerre Knudsen at her laboratory Lotte Bjerre Knudsen, who developed the liraglutide compound, pictured here in her laboratory at Novo Nordisk's R&D facility in Måløv, Denmark. |
 | Renewable energy In May 2007, Novo Nordisk signed a partnership agreement with the Danish energy company DONG Energy. Under the partnership, Novo Nordisk pledges to convert all energy savings realised at its Danish production into the purchase of green electricity from the new offshore wind farm at Horns Rev in the North Sea. |
 | Renewable energy With the partnership agreement Novo Nordisk has devised a cost-neutral way to significantly achieve reductions in CO2 emissions and help build the market for renewable energy in Denmark. When the wind farm is in full operation in 2010 it will secure Novo Nordisk’s Danish production a 100% green electricity supply and result in an annual CO2 reduction of 100,000 tons. |
 | Company Bikes Company bikes make it possible for employees to commute at major Novo Nordisk sites in Denmark. |
 | Company Bikes Close Up |
 | Company Bikes in use |
 | NordiFlex® Pens The next generation of NordiFlex® represents the latest advance in prefilled growth hormone pens from Novo Nordisk. |
 | NordiFlex® Penmate NordiFlex PenMate® with automatic needle insertion accessory for users of NordiFlex® who prefer a hidden needle when injectin. |
 | NordiPen® Customised NordiPen® with human growth hormone for treatment of growth disorders. |
